Therapeutic areas in pain management,Oncology, respiratory and etc

Napp pharmaceutical is actively involved in the following therapeutic areas:

•Analgesia
•Oncology
•Respiratory
•Cardiovascular
Analgesia is by far our largest therapeutic area, and we have over 15 different products currently available offering oral, transdermal and parenteral delivery of analgesia to suit the patient's needs. Over the years, we have introduced a number of products that have transformed the way we treat pain in the UK and across the globe. In the 1970s, we introduced the world's first prolonged release morphine sulphate tablets, which revolutionised the treatment of cancer pain. Since then, we have brought a number of innovations to the UK market, including the first 7-day analgesic patch and the first opioid agonist/antagonist combination tablet.

In 2004 we launched our first oncology product, and we have gone on to acquire a number of other products in this field, which are currently in clinical trials or under assessment by the regulatory authorities.

We also have a promising respiratory franchise. For a number of years, we have marketed prolonged release oral aminophylline and theophylline, but we are now branching out into inhaled products, with a number of products set for launch in the near future.

For more medical info visit http://www.napp.co.uk/Informationforhealthcarers/Pages/default.aspx